Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXRXLexicon Pharmaceuticals$2.29+3.2%$1.97$0.80▼$2.53$1.02B1.072.70 million shs3.39 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXRXLexicon Pharmaceuticals+2.55%+8.58%+2.55%+35.89%+187.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXRXLexicon Pharmaceuticals$2.29+3.2%$1.97$0.80▼$2.53$1.02B1.072.70 million shs3.39 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXRXLexicon Pharmaceuticals+2.55%+8.58%+2.55%+35.89%+187.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLXRXLexicon Pharmaceuticals 2.33Hold$4.5598.69% UpsideCurrent Analyst Ratings BreakdownLatest LXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026LXRXLexicon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.10(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLXRXLexicon Pharmaceuticals$49.80M20.43N/AN/A$0.30 per share7.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)Latest LXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLXRXLexicon Pharmaceuticals0.2418.8018.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLXRXLexicon Pharmaceuticals74.70%Insider OwnershipCompanyInsider OwnershipLXRXLexicon Pharmaceuticals14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableLXRX HeadlinesRecent News About These CompaniesHere's Why You Should Add LXRX Stock to Your Portfolio NowJune 22 at 11:41 AM | zacks.comIs Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comHow The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst UpdatesJune 4, 2026 | finance.yahoo.comLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsJune 3, 2026 | globenewswire.comLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comSA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRXMay 27, 2026 | msn.comLexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade)May 26, 2026 | seekingalpha.comCiti Raises its Price Target on Lexicon Pharmaceuticals (LXRX)May 22, 2026 | insidermonkey.comLexicon Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:LXRXMay 21, 2026 | benzinga.comLexicon Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 15, 2026 | seekingalpha.comLexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's ChangedMay 13, 2026 | finance.yahoo.comLexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comLexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk MilestonesMay 9, 2026 | insidermonkey.comLexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target MaintainedMay 8, 2026 | tipranks.comLexicon Pharmaceuticals Secures New Hercules Term Loan FacilityMay 7, 2026 | theglobeandmail.comLexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comLexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1May 7, 2026 | zacks.comLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesMay 7, 2026 | globenewswire.comLexicon Pharmaceuticals Q1 2026 earnings previewMay 6, 2026 | msn.comLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalMay 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX Company DescriptionsLexicon Pharmaceuticals NASDAQ:LXRX$2.29 +0.07 (+3.15%) Closing price 04:00 PM EasternExtended Trading$2.31 +0.02 (+0.87%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal MDA Space Targets US Defense Market With $620M Acquisition Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Cerebras Systems, Inc: The Next Rags-to-Riches AI Story? Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
